New approaches to invasive fungal infections

Current Opinion in Hematology

Volumn 10, Issue 6, 2003, Pages 445-450

  Marr, Kieren A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antifungal therapy; Fungal infections

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; MORTALITY; MYCOSIS; NEUTROPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS;

EID: 0242298744     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200311000-00009     Document Type: Review

References (63)

1. Wald A, Leisenring W, van Burik J, et al.: Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997, 175:1459-1466.
2. Grow W, Moreb J, Roque D, et al.: Late onset of invasive Aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marr Transplant 2002, 29:15-19. This study provides important data regarding risks for Aspergillus infections after transplant. Investigators used standardized criteria to define infection and provided results from multivariable models that included cumulative exposure to corticosteroids as a variable, which has typically been lacking in larger risk factor analyses.
3. Marr KA, Carter RA, Boeckh M, et al.: Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002, 100:4358-4366. This is the largest cohort of allogeneic BMT patients that has been evaluated to determine risks and outcomes of Aspergillus infections. Strengths include its size, use of standardized criteria to define infection, attention to host variables as risk factors, and multivariable modeling. Weaknesses include the fact that this represents only one transplant center's experience.
4. Martino R, Subira M, Rovira M, et al.: Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002, 116:475-482. Risk factors were reported from patients who were treated in multiple different transplant centers in Spain.
5. Baddley J, Stroud T, Salzman D, et al.: Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001, 32:1319-1324.
6. McWhinney P, Kibbler C, Hamon M, et al.: Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993, 17:397-404.
7. Sherertz RJ, Belani A, Kramer BS, et al.: Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987, 83:709-718.
8. Marr K, Carter R, Crippa F, et al.: Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002, 34:909-917. Incidence and outcomes of filamentous fungal infections that occurred in one transplant center over many years (1985-1998) were reported. This study is important as it provides a general outlook of the shifts in epidemiology over time; however, it lacks detailed risk factor analyses.
9. Fukuda T, Boeckh M, Carter RA, et al.: Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003, 102:827-833. Risks for fungal infections among a large cohort of patients who received nonmyeloablative conditioning were reported in this study. Multivariable modeling and probability curves provide important information regarding risks for infection: however, the results may not be applicable to patients who receive other nonmyeloablative conditioning regimens.
10. Junghanss C, Marr K, Carter R, et al.: Incidence of bacterial and fungal infections after nonmyeloablative compared to myeloablative allogeneic stem cell transplantation (HSCT). Biol Blood Marr Transplant 2002, 8:512-520.
11. Daly A, McAfee S, Dey B, et al.: Nonmyeloablative bone marrow transplantation: Infectious complications in 65 recipients of HLA-identical and mismatched transplants. Biol Blood Marrow Transplant 2003, 9:373-382. This retrospective study provides information regarding the types of infections that occur after nonmyeloablative BMT.
12. Hagen EA, Stern H, Porter D, et al.: High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003, 36:9-15.
13. Ascioglu A, Rex J, DePauw B, et al.: Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002, 34:7-14.
14. Anaissie EJ, Stratton SL, Dignani MC, et al.: Pathogenic Aspergillus species recovered from a hospital water system: a 3-year prospective study. Clin Infect Dis 2002, 34:780-789.
15. Anaissie EJ, Kuchar RT, Rex JH, et al.: Fusariosis associated with pathogenic fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001, 33:1871-1878.
16. Warris A, Voss A, Abrahamsen TG, et al.: Contamination of hospital water with Aspergillus fumigatus and other molds. Clin Infect Dis 2002, 34:1159-1160. This report provides an interesting theory regarding the source of water contamination with mold, with the suggestion that specific types of water delivery systems may be more prone to contamination. While there is a paucity of data to support this theory, it may explain variable results in different centers.
17. Panagopoulou P, Filioti J, Petrikkos G, et al.: Environmental surveillance of filamentous fungi in three tertiary care hospitals in Greece. J Hosp Infect 2002, 52:185-191.
18. Anaissie EJ, Stratton SL, Dignani MC, et al.: Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 2003, 101:2542-2546. Data indicating a potential association between waterborne filamentous fungi and disease in patients with hematologic malignancies is provided in this study. Strengths include the prospective nature of surveillance and details provided with regard to sampling methods. Investigators attempt to correlate water borne organisms with clinical isolates using molecular methods.
19. Raad I, Tarrand J, Hanna H, et al.: Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect Control Hosp Epidemiol 2002, 23:532-537.
20. Kontoyiannis D, Wessel V, Bodey G, et al.: Zygomycosis in the 1990s in a tertiary care center. Clin Infect Dis 2000, 30:851-856.
21. Boutati E, Anaissie E: Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
22. Idigoras P, Perez-Trallero E, Pineiro L, et al.: Disseminated infection and colonization by Scedosporium prolificans: a review of 18 cases, 1990-1999. Clin Infect Dis 2001, 32:E158-E165.
23. Guerrero A, Torres P, Duran MT, et al.: Airborne outbreak of nosocomial Scedosporium prolificans infection. Lancet 2001, 357:1267-1268.
24. Maertens J, Lagrou K, Deweerdt H, et al.: Disseminated infection by Scedosporium prolificans: an emerging fatality among haematology patients. Case report and review. Ann Hematol 2000, 79:340-344.
25. Cenci E, Perito S, Enssle K, et al.: Th 1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immunity 1997, 65:564-570.
26. Cenci E, Mencacci A: Fe d'Ostiani C, et al.: Cytokine-and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998, 178:1750-1760.
27. Cenci E, Mencacci A, Del Sero G, et al.: Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999, 180:1957-1968.
28. Cenci E, Mencacci A, Bacci A, et al.: T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000, 165:381-388.
29. Cenci E, Mencacci A, Spreca A, et al.: Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 2002, 70:2375-2382.
30. Ito J, Lyons J: Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis 2002, 186:869-871. Although this is a short report of a small animal study, results present intriguing possibilities with regard to potential application of vaccination approaches for fungal infections.
31. Hebart H, Bollinger C, Fisch P, et al.: Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002, 100:4521-4528. This is the first clinical study that has been performed to date to define, in a longitudinal fashion, T-cell responses to Aspergillus. Strengths include its novelty and use of well developed methods. Although the longitudinal analyses are informative, definitive conclusions await larger studies that incorporate more subjects with clinical data.
32. Maertens J, Verhaegen J, Lagrou K, et al.: Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001, 97:1604-1610.
33. Maertens J, Eldere JV, Verhaegen J, et al.: Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002, 186:1297-1306. This is a well done prospective study that uses standardized criteria to define aspergillosis and it provides some useful conclusions.
34. Herbrecht R, Letscher-Bru V, Oprea C, et al.: Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002, 20:1898-1906. Unlike other studies that have evaluated the use of diagnostic tests, this study goes a step further and explores the use of different cutoffs to define positivity and the potential importance of other biologic variables.
35. Spiess B, Buchheidt D, Baust C, et al.: Development of a LightCycler PCR assay for detection and quantification of Aspergillus fumigatus DNA in clinical samples from neutropenic patients. J Clin Microbiol 2003, 41:1811-1818.
36. Costa C, Costa J, Desterke C, et al.: Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002, 40:2224-2227. The comparative nature of this study provides particularly useful information regarding the relative performance of these assays.
37. Kawazu M, Kanda Y, Goyama S, et al.: Rapid diagnosis of invasive pulmonary aspergillosis by quantitative polymerase chain reaction using bronchial lavage fluid. Amer J Hematol 2003, 72:27-30.
38. Pham A, Tarrand J, May G, et al.: Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol 2003, 119:38-44.
39. Sanguinetti M, Posteraro B, Pagano L, et al.: Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003, 41:3922-3925.
40. Herbrecht R, Denning DW, Patterson TF, et al.: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415. This is the first randomized antifungal therapy trial performed for invasive aspergillosis. Its size and enrollment of patients with documented disease are particular strengths. Results show definitive differences between the two arms. The primary problem with this study is its design, as it compared voriconazole to amphotericin B primary therapy, followed by open-label antifungal therapies. As such, it compares two algorithms and does not provide definitive data regarding the utility of lipid formulations of amphotericin B.
41. Denning DW, Ribaud P, Milpied N, et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
42. Perfect JR, Marr KA, Walsh TJ, et al.: Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003, 36:1122-1131. This is a large study, and the numbers provide some information regarding the utility of voriconazole for less frequent infections, such as penicilliosis, Unfortunately, the "salvage" design presents questions regarding the use of this drug as primary therapy.
43. Fukuoka T, Johnston D, Winslow C, et al.: Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother 2003, 47:1213-1219. This is an elegant laboratory study that provides a great deal of insight regarding the mechanisms of action and the structural differences between voriconazole and fluconazole.
44. Bowman JC, Abruzzo GK, Anderson JW, et al.: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001, 45:3474-3481.
45. Bowman J, Hicks P, Kurtz M, et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002, 46:3001-3012. In this study, use of fluorescent probes provides information regarding how echinocandins function to inhibit Aspergillus growth.
46. Watabe E, Nakai T, Matsumoto S, et al.: Killing activity of micafungin against Aspergillus fumigatus hyphae assessed by specific fluorescent staining for cell viability. Antimicrob Agents Chemother 2003, 47:1995-1998.
47. Mora-Duarte J, Bitts R, Rotstein C, et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. New Eng J Med 2002, 347:2020-2029. This is a well done, randomized trial that establishes the utility of caspofungin for invasive candidiasis. Because of the design, one wonders how much the toxicities of amphotericin B contributed to lack of "successful therapy." This outlines the difficulties in doing randomized trials with this drug as a comparator.
48. Goodman D, Pamer E, Jakubowski A, et al.: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect Dis 2002, 35:E35-E36.
49. Mosquera J, Denning D: Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002, 46:556-557.
50. Diaz-Guerra T, Mallado E, Cuenca-Estrella M, et al.: A point mutation in the 14a-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003, 47:1120-1124.
51. Mann P, Parmegiani R, Wei S, et al.: Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 alpha-demethylase. Antimicrob Agents Chemother 2003, 47:577-581.
52. Morgenstern G, Prentice A, Prentice H, et al.: A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with hematological malignancies. Brit J Haematol 1999, 105:901-911.
53. Harousseau J, Dekker A, Stamatoullas-Bastard A, et al.: Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematologic malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. Antimicrob Agents Chemother 2000, 44:1887-1893.
54. Winston DJ, Maziarz RT, Chandrasekar PH, et al.: Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003, 138:705-713.
55. Sugar AM: Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob Agents Chemother 1995, 39:1907-1912.
56. Rex JH, Pappas PG, Karchmer AW, et al.: A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003, 36:1221-1228. This trial is important because it shows that the theoretic concern of combined azole and amphotericin therapy is negligible. The analyses of success of therapy according to the severity of underlying disease demonstrate a very important phenomenon that should be considered in design and interpretation of all studies of this type.
57. Shalit I, Shadkchan Y, Samra Z, et al.: In Vitro Synergy of Caspofungin and Itraconazole against Aspergillus spp.: MIC versus minimal effective concentration end points. Antimicrob Agents Chemother 2003, 47:141 6-1418.
58. Kirkpatrick WR, Perea S, Coco BJ, et al.: Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002, 46:2564-2568.
59. Perea S, Gonzalez G, Fothergill AW, et al.: In Vitro Interaction of Caspofungin Acetate with Voriconazole against Clinical Isolates of Aspergillus spp. Antimicrob Agents Chemother 2002, 46:3039-3041.
60. Arikan S, Lozano-Chiu M, Paetznick V, et al.: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002, 46:245-247.
61. Petraitis V, Petraitiene R, Sarafandi AA, et al.: Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003, 187:1834-1843.
62. Rubin M, Carroll K, Cahill B: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect Dis 2002, 34:1160. (letter)
63. Aliff TB, Maslak PG, Jurcic JG, et al.: Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003, 97:1025-1032.